Global Acute Vulvovaginal Candidiasis Treatment Market Size, Status and Forecast 2021-2027

1 Report Overview

• 1.1 Study Scope
• 1.2 Market Analysis by Type
  • 1.2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Clotrimazole
  • 1.2.3 Nystatin
  • 1.2.4 Fluconazole
  • 1.2.5 Ketoconazole
  • 1.2.6 Terbinafine
  • 1.2.7 Terconazole
  • 1.2.8 Others
• 1.3 Market by Application
  • 1.3.1 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hospital Pharmacies
  • 1.3.3 Retail Pharmacies
  • 1.3.4 Online Pharmacies
• 1.4 Study Objectives
• 1.5 Years Considered

2 Global Growth Trends

• 2.1 Global Acute Vulvovaginal Candidiasis Treatment Market Perspective (2016-2027)
• 2.2 Acute Vulvovaginal Candidiasis Treatment Growth Trends by Regions
  • 2.2.1 Acute Vulvovaginal Candidiasis Treatment Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Acute Vulvovaginal Candidiasis Treatment Historic Market Share by Regions (2016-2021)
  • 2.2.3 Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Regions (2022-2027)
• 2.3 Acute Vulvovaginal Candidiasis Treatment Industry Dynamic
  • 2.3.1 Acute Vulvovaginal Candidiasis Treatment Market Trends
  • 2.3.2 Acute Vulvovaginal Candidiasis Treatment Market Drivers
  • 2.3.3 Acute Vulvovaginal Candidiasis Treatment Market Challenges
  • 2.3.4 Acute Vulvovaginal Candidiasis Treatment Market Restraints

3 Competition Landscape by Key Players

• 3.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue
  • 3.1.1 Global Top Acute Vulvovaginal Candidiasis Treatment Players by Revenue (2016-2021)
  • 3.1.2 Global Acute Vulvovaginal Candidiasis Treatment Revenue Market Share by Players (2016-2021)
• 3.2 Global Acute Vulvovaginal Candidiasis Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Players Covered: Ranking by Acute Vulvovaginal Candidiasis Treatment Revenue
• 3.4 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio
  • 3.4.1 Global Acute Vulvovaginal Candidiasis Treatment Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Acute Vulvovaginal Candidiasis Treatment Revenue in 2020
• 3.5 Acute Vulvovaginal Candidiasis Treatment Key Players Head office and Area Served
• 3.6 Key Players Acute Vulvovaginal Candidiasis Treatment Product Solution and Service
• 3.7 Date of Enter into Acute Vulvovaginal Candidiasis Treatment Market
• 3.8 Mergers & Acquisitions, Expansion Plans

4 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Type

• 4.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Type (2016-2021)
• 4.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Type (2022-2027)

5 Acute Vulvovaginal Candidiasis Treatment Breakdown Data by Application

• 5.1 Global Acute Vulvovaginal Candidiasis Treatment Historic Market Size by Application (2016-2021)
• 5.2 Global Acute Vulvovaginal Candidiasis Treatment Forecasted Market Size by Application (2022-2027)

6 North America

• 6.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
• 6.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  • 6.2.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
  • 6.2.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
  • 6.2.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
• 6.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  • 6.3.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
  • 6.3.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
  • 6.3.3 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
• 6.4 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  • 6.4.1 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
  • 6.4.2 North America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.3 Canada

7 Europe

• 7.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
• 7.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  • 7.2.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
  • 7.2.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
  • 7.2.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
• 7.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  • 7.3.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
  • 7.3.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
  • 7.3.3 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
• 7.4 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  • 7.4.1 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
  • 7.4.2 Europe Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic

8 Asia-Pacific

• 8.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
• 8.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  • 8.2.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
• 8.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  • 8.3.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
• 8.4 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region
  • 8.4.1 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Acute Vulvovaginal Candidiasis Treatment Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia

9 Latin America

• 9.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
• 9.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  • 9.2.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
  • 9.2.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
  • 9.2.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
• 9.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  • 9.3.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
  • 9.3.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
  • 9.3.3 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
• 9.4 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  • 9.4.1 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
  • 9.4.2 Latin America Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil

10 Middle East & Africa

• 10.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size (2016-2027)
• 10.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type
  • 10.2.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Type (2016-2027)
• 10.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application
  • 10.3.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Application (2016-2027)
• 10.4 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country
  • 10.4.1 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Acute Vulvovaginal Candidiasis Treatment Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE

11 Key Players Profiles

• 11.1 Mycovia Pharmaceuticals, Inc
  • 11.1.1 Mycovia Pharmaceuticals, Inc Company Details
  • 11.1.2 Mycovia Pharmaceuticals, Inc Business Overview
  • 11.1.3 Mycovia Pharmaceuticals, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.1.4 Mycovia Pharmaceuticals, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.1.5 Mycovia Pharmaceuticals, Inc Recent Development
• 11.2 Scynexis, Inc
  • 11.2.1 Scynexis, Inc Company Details
  • 11.2.2 Scynexis, Inc Business Overview
  • 11.2.3 Scynexis, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.2.4 Scynexis, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.2.5 Scynexis, Inc Recent Development
• 11.3 Basilea Pharmaceutica Ltd
  • 11.3.1 Basilea Pharmaceutica Ltd Company Details
  • 11.3.2 Basilea Pharmaceutica Ltd Business Overview
  • 11.3.3 Basilea Pharmaceutica Ltd Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.3.4 Basilea Pharmaceutica Ltd Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.3.5 Basilea Pharmaceutica Ltd Recent Development
• 11.4 Astellas Pharma Inc
  • 11.4.1 Astellas Pharma Inc Company Details
  • 11.4.2 Astellas Pharma Inc Business Overview
  • 11.4.3 Astellas Pharma Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.4.4 Astellas Pharma Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.4.5 Astellas Pharma Inc Recent Development
• 11.5 Grupo Ferrer Internacional, S.A
  • 11.5.1 Grupo Ferrer Internacional, S.A Company Details
  • 11.5.2 Grupo Ferrer Internacional, S.A Business Overview
  • 11.5.3 Grupo Ferrer Internacional, S.A Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.5.4 Grupo Ferrer Internacional, S.A Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.5.5 Grupo Ferrer Internacional, S.A Recent Development
• 11.6 Pacgen Life Science Corporation
  • 11.6.1 Pacgen Life Science Corporation Company Details
  • 11.6.2 Pacgen Life Science Corporation Business Overview
  • 11.6.3 Pacgen Life Science Corporation Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.6.4 Pacgen Life Science Corporation Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.6.5 Pacgen Life Science Corporation Recent Development
• 11.7 NovaDigm Therapeutics, Inc
  • 11.7.1 NovaDigm Therapeutics, Inc Company Details
  • 11.7.2 NovaDigm Therapeutics, Inc Business Overview
  • 11.7.3 NovaDigm Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.7.4 NovaDigm Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.7.5 NovaDigm Therapeutics, Inc Recent Development
• 11.8 Cidara Therapeutics, Inc
  • 11.8.1 Cidara Therapeutics, Inc Company Details
  • 11.8.2 Cidara Therapeutics, Inc Business Overview
  • 11.8.3 Cidara Therapeutics, Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.8.4 Cidara Therapeutics, Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.8.5 Cidara Therapeutics, Inc Recent Development
• 11.9 Amplyx Pharmaceuticals Inc
  • 11.9.1 Amplyx Pharmaceuticals Inc Company Details
  • 11.9.2 Amplyx Pharmaceuticals Inc Business Overview
  • 11.9.3 Amplyx Pharmaceuticals Inc Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.9.4 Amplyx Pharmaceuticals Inc Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.9.5 Amplyx Pharmaceuticals Inc Recent Development
• 11.10 Pfizer, Inc.
  • 11.10.1 Pfizer, Inc. Company Details
  • 11.10.2 Pfizer, Inc. Business Overview
  • 11.10.3 Pfizer, Inc. Acute Vulvovaginal Candidiasis Treatment Introduction
  • 11.10.4 Pfizer, Inc. Revenue in Acute Vulvovaginal Candidiasis Treatment Business (2016-2021)
  • 11.10.5 Pfizer, Inc. Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

• 13.1 Research Methodology
  • 13.1.1 Methodology/Research Approach
  • 13.1.2 Data Source
• 13.2 Disclaimer